UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 39

Sortiert nach

Intravascular Large B-Cell Lymphoma: A Review with a Focus on the Prognostic Value of Skin Involvement

Current oncology (Toronto), 2022-04, Vol.29 (5), p.2909-2919

2022

Volltextzugriff (PDF)

MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1–2a trial

The Lancet. Haematology, 2020-05, Vol.7 (5), p.e381-e394

2020

Volltextzugriff (PDF)

BRAF inhibitor treatment in classic hairy cell leukemia: a long-term follow-up study of patients treated outside clinical trials

Leukemia, 2020-05, Vol.34 (5), p.1454-1457

2020

Volltextzugriff (PDF)

MOR202 with Low-Dose Dexamethasone (Dex) or Pomalidomide/Dex or Lenalidomide/Dex in Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis of a Phase I/IIa, Multicenter, Dose-Escalation Study

Blood, 2018-11, Vol.132 (Supplement 1), p.153-153

2018

Volltextzugriff (PDF)

P-034 Alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA × CD3 T-cell engager, in patients (pts) with relapsed/refractory multiple myeloma (RRMM): latest results from a phase 1 first-in-human clinical study

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S52-S53

2023

Volltextzugriff (PDF)

MOR202 with low-dose dexamethasone (Dex) and in combination with pomalidomide/dex and lenalidomide/dex in relapsed or refractory multiple myeloma (RRMM): Interim analysis of a phase I/IIa dose-escalation study

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.8024-8024

2017

Volltextzugriff (PDF)

Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial

The Lancet. Haematology, 2024-02, Vol.11 (2), p.e101-e113

2024

Volltextzugriff (PDF)

A Phase I/IIa Study of the CD38 Antibody MOR202 Alone and in Combination with Pomalidomide or Lenalidomide in Patients with Relapsed or Refractory Multiple Myeloma

Blood, 2016-12, Vol.128 (22), p.1152-1152

2016

Volltextzugriff (PDF)

MOR202 alone and in combination with pomalidomide or lenalidomide in relapsed or refractory multiple myeloma: Data from clinically relevant cohorts from a phase I/IIa study

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.8012-8012

2016

Volltextzugriff (PDF)

Phase I/IIa Study of the Human Anti-CD38 Antibody MOR202 (MOR03087) in Relapsed or Refractory Multiple Myeloma

Blood, 2015-12, Vol.126 (23), p.3035-3035

2015

Volltextzugriff (PDF)

A phase I/IIa study of the human anti-CD38 antibody MOR202 (MOR03087) in relapsed or refractory multiple myeloma (rrMM)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.8574-8574

2015

Volltextzugriff (PDF)

A phase I/IIa Study of the CD38 Antibody MOR202 in Combination With Pomalidomide or Lenalidomide in Patients With Relapsed or Refractory Multiple Myeloma

Clinical lymphoma, myeloma and leukemia, 2017-02, Vol.17 (1), p.e61-e61

2017

Volltextzugriff (PDF)

Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption

Antiviral therapy, 2005-01, Vol.10 (2), p.285-300

2005

Volltextzugriff (PDF)

Blinatumomab Monotherapy Shows Efficacy in Patients with Relapsed Diffuse Large B Cell Lymphoma

Blood, 2011-11, Vol.118 (21), p.1637-1637

2011

Volltextzugriff (PDF)

Einmischen necessary: Gesellschaftliche Verantwortung und politische Beteiligung in der Erlebnispädagogik

1. Aufl., 2021

Volltextzugriff (PDF)

XXI. Congress of the ICLA: Proceedings. Dialogues between Media

Ferstl, Paul

2021

Volltextzugriff (PDF)

Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β, and TNF-α: Receptors, functions, and roles in diseases

Journal of allergy and clinical immunology, 2016-10, Vol.138 (4), p.984-1010

2016

Volltextzugriff (PDF)

Einmischen possible: Die gesellschaftspolitische Dimension der Erlebnispädagogik

1. Auflage 2018, 2018

Volltextzugriff (PDF)

TLR13 Recognizes Bacterial 23S rRNA Devoid of Erythromycin Resistance—Forming Modification

Science (American Association for the Advancement of Science), 2012-08, Vol.337 (6098), p.1111-1115

2012

Volltextzugriff (PDF)

The social and socio-political embeddedness of COVID-19 vaccination decision-making: A five-country qualitative interview study from Europe

Vaccine, 2023-03, Vol.41 (12), p.2084-2092

2023

Volltextzugriff (PDF)

IL‐10 induces IgG4 production in NOD‐scid Il2rγnull mice humanized by engraftment of peripheral blood mononuclear cells

Allergy (Copenhagen), 2021-11, Vol.76 (11), p.3525-3529

2021

Volltextzugriff (PDF)

Generating Emotionally Expressive Look-At Animation

Proceedings of the 16th ACM SIGGRAPH Conference on Motion, Interaction and Games, 2023, p.1-6

2023

Volltextzugriff (PDF)

Diagnosing deficits in quality of life and providing tailored therapeutic options: Results of a randomised trial in 220 patients with colorectal cancer

European journal of cancer (1990), 2020-05, Vol.130, p.102-113

2020

Volltextzugriff (PDF)

1 – 25 von 39

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(36)

Publikationsform

Sprache

Englisch
(31)
Deutsch
(9)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Intravascular Large B-Cell Lymphoma: A Review with a Focus on the Prognostic Value of Skin Involvement

P883: ALNUCTAMAB (ALNUC; BMS‐986349; CC‐93269), A BCMA × CD3 T‐CELL ENGAGER, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): LATEST RESULTS FROM A PHASE 1 FIRST‐IN‐HUMAN CLINICAL STUDY

CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial

MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1–2a trial

BRAF inhibitor treatment in classic hairy cell leukemia: a long-term follow-up study of patients treated outside clinical trials

MOR202 with Low-Dose Dexamethasone (Dex) or Pomalidomide/Dex or Lenalidomide/Dex in Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis of a Phase I/IIa, Multicenter, Dose-Escalation Study

P-034 Alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA × CD3 T-cell engager, in patients (pts) with relapsed/refractory multiple myeloma (RRMM): latest results from a phase 1 first-in-human clinical study

MOR202 with low-dose dexamethasone (Dex) and in combination with pomalidomide/dex and lenalidomide/dex in relapsed or refractory multiple myeloma (RRMM): Interim analysis of a phase I/IIa dose-escalation study

Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial

A Phase I/IIa Study of the CD38 Antibody MOR202 Alone and in Combination with Pomalidomide or Lenalidomide in Patients with Relapsed or Refractory Multiple Myeloma

MOR202 alone and in combination with pomalidomide or lenalidomide in relapsed or refractory multiple myeloma: Data from clinically relevant cohorts from a phase I/IIa study

Phase I/IIa Study of the Human Anti-CD38 Antibody MOR202 (MOR03087) in Relapsed or Refractory Multiple Myeloma

A phase I/IIa study of the human anti-CD38 antibody MOR202 (MOR03087) in relapsed or refractory multiple myeloma (rrMM)

A phase I/IIa Study of the CD38 Antibody MOR202 in Combination With Pomalidomide or Lenalidomide in Patients With Relapsed or Refractory Multiple Myeloma

Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption

Blinatumomab Monotherapy Shows Efficacy in Patients with Relapsed Diffuse Large B Cell Lymphoma

Einmischen necessary: Gesellschaftliche Verantwortung und politische Beteiligung in der Erlebnispädagogik

XXI. Congress of the ICLA: Proceedings. Dialogues between Media

Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β, and TNF-α: Receptors, functions, and roles in diseases

Einmischen possible: Die gesellschaftspolitische Dimension der Erlebnispädagogik

TLR13 Recognizes Bacterial 23S rRNA Devoid of Erythromycin Resistance—Forming Modification

The social and socio-political embeddedness of COVID-19 vaccination decision-making: A five-country qualitative interview study from Europe

IL‐10 induces IgG4 production in NOD‐scid Il2rγnull mice humanized by engraftment of peripheral blood mononuclear cells

Generating Emotionally Expressive Look-At Animation

Diagnosing deficits in quality of life and providing tailored therapeutic options: Results of a randomised trial in 220 patients with colorectal cancer

Suchergebnisse filtern